Synvisc Injection denied? Start your appeal.
Start with the reason on your denial notice. Check your plan’s appeal route, then gather the records that answer the specific coverage rule.
No account or payment to check your route. You confirm the plan facts; published review outcomes do not predict your result.
Free evidence checklist for knee osteoarthritis
What to gather for a knee injection appeal
Use the published decisions to ask better questions, then answer the exact rule in your denial. Bring this checklist to your treating clinician; it does not tell you which treatment to choose.
Download blank checklist (.txt)- The denial and the applicable rule. Keep the complete notice, notice date, filing deadline, recipient, and the exact plan policy or criterion cited. Ask which benefit covers the injection and whether the dispute is medical necessity, a preferred product, repeat timing, or a billing issue.
- Diagnosis, knee, and functional limits. Ask the clinician to identify the affected knee, diagnosis, relevant imaging report, and how pain limits walking, standing, or other daily activities. Do not infer a diagnosis from pain alone.
- Conservative care already tried. List each treatment, dates, duration, response, and adverse effects. Include non-drug approaches and medicines where relevant. Ask the clinician to explain any contraindication instead of treating a contraindicated therapy as a required trial.
- Why this product and this request. Ask the prescriber to answer the actual denial criterion, explain the individual rationale, and check the requested dose and schedule against current product labeling. Approval of one hyaluronic-acid product does not establish coverage for every product.
- If this is a repeat series. Record prior injection dates, which knee was treated, measurable pain and function changes, when symptoms returned, and why the timing satisfies the applicable policy. A first series and a repeat series can have different criteria.
- A complete submission record. Match each disputed criterion to an attachment. Confirm the governing appeal route, send it using the notice instructions, and keep the submission receipt. Ask the clinician about an urgent review if waiting could seriously harm health.
Coverage criteria and clinical guidance are different
For example, Medicare LCD L39260 requires documented symptomatic knee osteoarthritis, radiographic support, a qualifying conservative-care history, and other criteria. Repeat treatment has separate requirements, including a prior response and a minimum interval. This is a local policy: verify the contractor, service date, and complete rule before relying on it.
AAOS does not recommend hyaluronic-acid injections for routine knee osteoarthritis use. Favorable historical reviews do not erase that limitation. Ask the clinician to explain the individual rationale and address the plan's criteria. For Monovisc, consult the FDA approval record and current labeling; FDA approval is not a coverage guarantee.
U.S. self-help preparation for knee osteoarthritis injection denials; not medical or legal advice. The historical California review rate is not your chance of success. L39260 is a local Medicare policy, not a nationwide rule for every plan. Confirm contractor jurisdiction, service date, and the policy in your notice. Clinical guidance and FDA labeling do not guarantee insurance coverage. Sources reviewed 2026-09-05.
- FDA: Monovisc approval record and labeling
- CMS: local coverage determination L39260
- AAOS: knee osteoarthritis clinical guideline
The download is a blank, printable worksheet. Fill it in privately; nothing you write in the downloaded file is sent to Coverage Rights.
In the California DMHC record, independent physician reviewers decided 95 published external-review cases involving Synvisc Injection and overturned the plan’s denial in 71.6%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Osteoarthritis Of The Knee | 45 | 86.7% |
| Knee Osteoarthritis | 19 | 63.2% |
| Osteoarthritis | 12 | 83.3% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 91 | 72.5% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 4 | 50% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found that the patient has requested authorization and coverage for a Synvisc injection to the left knee. The Health Plan has denied the request indicating that the requested medication is not medically necessary.At issue, in this case, is whether the requested Synvisc injection is medically necessary for the treatment of the patient’s medical condition.According to researchers, intra-articular hyaluronic acid provides a moderate symptomatic benefit to patients with knee osteoarthritis without major safety concerns. In fact, viscosupplementation may offer one of the best benefit/risk ratios among pharmacologic options, as measured by improvements in knee osteoarthritis symptoms, the overall gain in quality of life and substantial delay in time to total knee replacement.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Synvisc injections. The Health Plan has denied this request indicating that the requested injections are not medically necessary for treatment of the enrollee’s bilateral knee osteoarthritis.At issue in this case is whether the requested Synvisc injections are medically necessary for treatment of the enrollee’s medical condition.As evidenced by the patient’s history of significant benefit from prior injections, the current literature continues to support the use of viscosupplementation for osteoarthritis of the knees.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: A patient requested authorization and coverage for bilateral knee Synvisc injections. The Health Plan has denied this request indicating that the requested medication is not medically necessary for treatment of the patient’s osteoarthritis of the knees, bilateral. The submitted documentation does not support the medical necessity of the requested medication. The most recent guidelines for the management of knee osteoarthritis do not recommend hyaluronic acid injections. The 2014 Osteoarthritis Research Society International (OARSI) states that for Osteoarthritis (OA) of the knee, appropriate treatment modalities for all individuals with knee OA included biomechanical interventions, intra-articular corticosteroids, land-based and water-based exercise, self-management and education, strength training, and weight management.
Nature of Statutory Criteria/Case Summary: A patient requested Synvisc injections in the knees. Findings: The physician reviewer found that the medical evidence does not support repeat hyaluronic acid injections if there is no documentation of significant improvement in symptoms for six months or more. Hyaluronic acid injections in the knee are recommended as a possible option for patients with significantly symptomatic severe knee osteoarthritis who have not responded adequately to recommended conservative treatments for at least three months, including failure to adequately respond to aspiration and injection of intra-articular steroids. The medical evidence supports hyaluronic acid injections to potentially delay total knee replacement for patients with pain that interferes with functional activities.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Synvisc Injection, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY